{
    "organizations": [],
    "uuid": "9adea28443384029b4912f39cf97d0cea9bde47e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-alexion-reports-q1-results-and-pos/brief-alexion-reports-q1-results-and-positive-topline-data-from-alxn1210-phase-3-pnh-switch-study-idUSASC09XM7",
    "ord_in_thread": 0,
    "title": "Alexion Reports Q1 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 26 (Reuters) - Alexion Pharmaceuticals Inc:\n* ALEXION REPORTS FIRST QUARTER 2018 RESULTS AND POSITIVE TOPLINE DATA FROM ALXN1210 PHASE 3 PNH SWITCH STUDY\n* Q1 NON-GAAP EARNINGS PER SHARE $1.68\n* Q1 GAAP EARNINGS PER SHARE $1.11 * Q1 REVENUE $930.9 MILLION VERSUS I/B/E/S VIEW $923.5 MILLION\n* Q1 EARNINGS PER SHARE VIEW $1.50 — THOMSON REUTERS I/B/E/S\n* REGULATORY SUBMISSIONS FROM ALXN1210 PHASE 3 PNH NAIVE AND SWITCH STUDIES PLANNED IN U.S. AND EU IN MID-2018\n* ALEXION PHARMACEUTICALS - ALXN1210 WAS GENERALLY WELL TOLERATED IN PHASE 3 SWITCH STUDY WITH A SAFETY PROFILE THAT IS CONSISTENT WITH THAT FOR SOLIRIS\n* ALEXION - PHASE 3 SWITCH STUDY SHOWED NON-INFERIORITY OF ALXN1210 TO SOLIRIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO HAD BEEN STABLE ON SOLIRIS\n* PHASE 3 SWITCH STUDY ALSO DEMONSTRATED NON-INFERIORITY ON ALL FOUR KEY SECONDARY ENDPOINTS\n* SEES 2018 TOTAL REVENUES $3,925 TO $3,985 MILLION * SEES 2018 SOLIRIS REVENUES OF $3,380 MILLION TO $3,420 MILLION\n* SEES 2018 EARNINGS PER SHARE $1.35 TO $1.75 * SEES 2018 NON-GAAP EARNINGS PER SHARE $6.75 TO $6.90\n* FY2018 EARNINGS PER SHARE VIEW $6.86, REVENUE VIEW $3.98 BILLION — THOMSON REUTERS I/B/E/S\n* ALEXION - 2018 FINANCIAL GUIDANCE ASSUMES UNFAVORABLE SOLIRIS REVENUE IMPACT OF $90-$110 MILLION FROM ALXN1210 & OTHER CLINICAL TRIAL RECRUITMENT VERSUS PRIOR YEAR\n* EXPECTS TO INCUR ADDITIONAL RESTRUCTURING AND RELATED EXPENSES OF APPROXIMATELY $15 MILLION TO $80 MILLION IN 2018 Source text for Eikon:\n ",
    "published": "2018-04-26T18:36:00.000+03:00",
    "crawled": "2018-04-27T16:42:38.014+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "alexion",
        "pharmaceutical",
        "inc",
        "alexion",
        "report",
        "first",
        "quarter",
        "result",
        "positive",
        "topline",
        "data",
        "alxn1210",
        "phase",
        "pnh",
        "switch",
        "study",
        "q1",
        "earnings",
        "per",
        "share",
        "q1",
        "gaap",
        "earnings",
        "per",
        "share",
        "q1",
        "revenue",
        "million",
        "versus",
        "view",
        "million",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "regulatory",
        "submission",
        "alxn1210",
        "phase",
        "pnh",
        "naive",
        "switch",
        "study",
        "planned",
        "eu",
        "alexion",
        "pharmaceutical",
        "alxn1210",
        "generally",
        "well",
        "tolerated",
        "phase",
        "switch",
        "study",
        "safety",
        "profile",
        "consistent",
        "soliris",
        "alexion",
        "phase",
        "switch",
        "study",
        "showed",
        "alxn1210",
        "soliris",
        "patient",
        "paroxysmal",
        "nocturnal",
        "hemoglobinuria",
        "stable",
        "soliris",
        "phase",
        "switch",
        "study",
        "also",
        "demonstrated",
        "four",
        "key",
        "secondary",
        "endpoint",
        "see",
        "total",
        "revenue",
        "million",
        "see",
        "soliris",
        "revenue",
        "million",
        "million",
        "see",
        "earnings",
        "per",
        "share",
        "see",
        "earnings",
        "per",
        "share",
        "fy2018",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "billion",
        "thomson",
        "reuters",
        "alexion",
        "financial",
        "guidance",
        "assumes",
        "unfavorable",
        "soliris",
        "revenue",
        "impact",
        "million",
        "alxn1210",
        "clinical",
        "trial",
        "recruitment",
        "versus",
        "prior",
        "year",
        "expects",
        "incur",
        "additional",
        "restructuring",
        "related",
        "expense",
        "approximately",
        "million",
        "million",
        "source",
        "text",
        "eikon"
    ]
}